Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis

Código QR

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis

Wenyu Ye,1 Haya Ascher-Svanum,2 Yuka Tanji,3 Jennifer A Flynn,3 Michihiro Takahashi,3,4 Robert R Conley21Lilly Suzhou Pharmaceutical Co, Ltd, Shanghai, People&rsquo;s Republic of China; 2Eli Lilly and Company, Indianapolis, IN, USA; 3Lilly Research Laboratories Japan, Eli Lilly Japan KK, Kob...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takahashi M, Flynn JA, Tanji Y, Ascher-Svanum H, Ye W, Conley RR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/bd088a5a901348708a0a804aa632c09a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum H, et al.
Publicado: (2014)

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
por: Hong Liu-Seifert, et al.
Publicado: (2009)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
por: Adel Gabriel
Publicado: (2010)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs L, et al.
Publicado: (2013)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao K, et al.
Publicado: (2013)

Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
por: Katagiri H, et al.
Publicado: (2018)

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
por: Ascher-Svanum H, et al.
Publicado: (2012)

COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES
por: Shiraz Hussain, et al.
Publicado: (2021)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
por: Katagiri H, et al.
Publicado: (2018)

Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?
por: Montgomery W, et al.
Publicado: (2014)

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
por: Liang Y, et al.
Publicado: (2017)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: JP Lindenmayer
Publicado: (2010)

Effects of risperidone and olanzapine on remnant-like lipoprotein particle cholesterol (RLP-C) in schizophrenic patients
por: Takahiko Nagamine
Publicado: (2008)

Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study
por: Gabriel A
Publicado: (2013)

Clinical utility of the risperidone formulations in the management of schizophrenia
por: Madaan V, et al.
Publicado: (2011)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara N, et al.
Publicado: (2019)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
por: Ciudad A, et al.
Publicado: (2013)

Agomelatine as monotherapy for major depression: an outpatient, open-label study
por: Pecenak J, et al.
Publicado: (2013)

Olanzapine–valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group
por: Xu L, et al.
Publicado: (2015)

Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia
por: Jeffrey R Bishop, et al.
Publicado: (2008)

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
por: Pecenak J, et al.
Publicado: (2013)

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
por: Louz&atilde; M, et al.
Publicado: (2011)

Risperidone improves interpersonal perception and executive function in patients with schizophrenia
por: Zhou Z, et al.
Publicado: (2016)

Atypical antipsychotics in the treatment of early-onset schizophrenia
por: Hrdlicka M, et al.
Publicado: (2015)

Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine
por: Montgomery W, et al.
Publicado: (2015)

Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia
por: Yang F, et al.
Publicado: (2018)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
por: Citrome L, et al.
Publicado: (2019)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Rosaria Di Lorenzo, et al.
Publicado: (2010)

Antipsychotics and risk of natural death in patients with schizophrenia
por: Chen Y, et al.
Publicado: (2019)

Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia
por: Hongyan Zhang, et al.
Publicado: (2011)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
por: Zhao Y, et al.
Publicado: (2013)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
por: Dhiren Singh, et al.
Publicado: (2009)

Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
por: Xinhua&nbsp;S Ren, et al.
Publicado: (2009)

The cost of schizophrenia in Japan
por: Sado M, et al.
Publicado: (2013)

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
por: &Uuml;nsal C, et al.
Publicado: (2013)

Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study
por: Strzelecki D, et al.
Publicado: (2015)

The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia
por: Wu X, et al.
Publicado: (2014)

Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis
por: Hýža M, et al.
Publicado: (2021)

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar&nbsp;I disorder
por: Delia Bishara, et al.
Publicado: (2009)

A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia
por: Suzuki H, et al.
Publicado: (2013)